TY  - JOUR
PB  - Ovid Technologies (Wolters Kluwer Health)
ID  - discovery10203097
N2  - There is a new awareness of the widespread nature of metabolic dysfunction-associated steatotic liver disease (MASLD) and its connection to cardiovascular disease (CVD). This has catalyzed collaboration between cardiologists, hepatologists, endocrinologists, and the wider multidisciplinary team to address the need for earlier identification of those with MASLD who are at increased risk for CVD. The overlap in the pathophysiologic processes and parallel prevalence of CVD, metabolic syndrome, and MASLD highlight the multisystem consequences of poor cardiovascular-liver-metabolic health. Metabolic dysfunction and associated insulin resistance, together with the predilection for ectopic fat deposition in the liver and surrounding tissues, are associated with elevated risk of endothelial dysfunction, systemic inflammatory response, and ectopic fat deposition in the epicardium. This complex pathophysiology can accelerate atherogenic dyslipidemia, atherogenesis, diastolic dysfunction, valvular calcification, and cardiac arrhythmias. Despite the mounting evidence of mechanistic pathways underpinning MASLD and CVD, current recommendations have not clearly focused upon MASLD as a risk factor or target for intervention in CVD. We have brought together a diverse range of international experts committed to promoting cardiovascular-liver-metabolic health and related outcomes across the globe. The overarching goal of this document is to offer a construct for clinicians in the cardiovascular field with regards to (1) diagnosis and screening of MASLD through the use of noninvasive serum and imaging tests; (2) screening for CVD in all individuals with MASLD regardless of established atherosclerotic risk factors; and (3) the approach to management of MASLD with respect to prevention of CVD through lifestyle, as well as pharmacologic and surgical strategies. To achieve this, the modified Delphi method was applied and a series of evidence-based quality standard recommendations have been identified.
KW  - atherosclerosis
KW  -  cardiovascular diseases
KW  -  Cardiovascular Diseases
KW  -  Delphi Technique
KW  -  fatty liver
KW  -  Fatty Liver
KW  -  Humans
KW  -  isk factors
KW  -  liver diseases
KW  -  Mass Screening
KW  -  metabolic syndrome
KW  -  Metabolic Syndrome
KW  -  Risk Factors
EP  - 119
Y1  - 2025/01/07/
AV  - restricted
TI  - Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach
SN  - 0009-7322
UR  - https://doi.org/10.1161/circulationaha.124.070535
A1  - Chew, Nicholas WS
A1  - Mehta, Anurag
A1  - Goh, Rachel Sze Jen
A1  - Zhang, Audrey
A1  - Chen, Yiming
A1  - Chong, Bryan
A1  - Chew, Han Shi Jocelyn
A1  - Shabbir, Asim
A1  - Brown, Adrian
A1  - Dimitriadis, Georgios K
A1  - Huang, Daniel Q
A1  - Foo, Roger
A1  - le Roux, Carel W
A1  - Figtree, Gemma A
A1  - Fudim, Marat
A1  - Pandey, Ambarish
A1  - Mamas, Mamas A
A1  - Hausenloy, Derek J
A1  - Richards, A Mark
A1  - Nicholls, Stephen J
A1  - Chan, Mark Y
A1  - Muthiah, Mark D
A1  - Sanyal, Arun
A1  - Sperling, Laurence S
JF  - Circulation
VL  - 151
SP  - 98
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher?s terms and conditions.
IS  - 1
ER  -